No Prescription |
 |
 | ||
|
IDROFOS Boniva |
|
| ||
No Prescription » Prescription Drugs 9 » IDROFOS Boniva Ibandronate is used to prevent and treat certain types of bone loss (osteoporosis). Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause as you age or if you take corticosteroid medications (e.g. prednisone) for long periods.This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Ibandronate belongs to a class of medications called bisphosphonates.How to use Ibandronate OralRead the Patient Information Leaflet before starting this medication and each time you get a refill because new information may be available. Follow the instructions very closely to maximize the amount of drug absorbed and reduce the risk of injury to your esophagus. Consult your doctor or pharmacist if you have any questions.Take this medication by mouth usually once a month or as directed by your doctor. Take this medication after getting up for the day before taking your first food beverage or other medication. Do not take it at bedtime or while you are still in bed.Take this medication with a full glass (6-8 ounces or 180-240 milliliters) of plain water. Do not take it with any other beverages. Do not chew or suck the tablet or keep it in your mouth to melt. Swallow the tablet whole. Then stay fully upright (sitting standing or walking) for at least 60 minutes and do not lie down until after your first food of the day. Wait at least 60 minutes after taking ibandronate before you eat or drink anything other than plain water and before taking any other medication by mouth.Medications such as quinapril certain forms of didanosine (chewable/dispersible buffered tablets or pediatric oral solution) sucralfate and bismuth subsalicylate may interfere with the absorption of ibandronate. Calcium or iron supplements vitamins with minerals and antacids containing calcium magnesium or aluminum as well as foods such as dairy products (e.g. milk yogurt) mineral water and calcium-enriched juice may also interfere with absorption. Do not take these products for at least 60 minutes after taking ibandronate.Take this medication regularly in order to get the most benefit from it. Remember to take it at the same time each morning.Ibandronate Oral is used to treat the following:Decreased Bone Mass Following Menopause Post-Menopausal Osteoporosis Prevention Buy IDROFOS Boniva and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About IDROFOS Boniva: Product Type: Prescription Drugs 9 IDROFOS ( Boniva Bondria Generic Ibandronate Sodium ) IDROFOS (Boniva Bondria Generic Ibandronate Sodium) Boniva Bondria Generic Ibandronate Sodium 150mg 3 Tablet 5 x 3 Tablets 3 x 3 Tablets Boniva Bondria Generic Ibandronate Sodium IDROFOS
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
